Patients in the highest TG/HDL quartile (Q4) had a significantly increased 28-day mortality risk, with odds ratios ranging ...
Researchers have found in a new research that in the early post-transplant phase, greater daily protein intake was associated with better kidney graft function, enhanced lipid metabolism, ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, ...
Company will host an R&D investor webcast on Monday, June 2, at 11:00 am CDT to review updated RAMP 205 data as well as updated data on GFH375 presented at the ASCO 2025 Annual Meeting GenFleet ...
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback